Go Pro
LON:GENF

Genflow Biosciences Final Earnings Report

Genflow Biosciences logo
GBX 1.84 -0.20 (-9.66%)
As of 06:55 AM Eastern

Genflow Biosciences EPS Results

Actual EPS
-GBX 0.47
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genflow Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genflow Biosciences Announcement Details

Quarter
Final
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Genflow Biosciences Earnings Headlines

SIRT6 gene therapy shows promise in aged dogs - ICYMI
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Genflow Biosciences PLC Announces Notice of AGM
See More Genflow Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genflow Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genflow Biosciences and other key companies, straight to your email.

About Genflow Biosciences

Genflow Biosciences (LON:GENF) is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.

View Genflow Biosciences Profile